Cormedix vs Krystal Biotech
Krystal Biotech is the larger business, with $389m of revenue in fiscal 2025 against $312m for Cormedix (1.2 times as much). Cormedix grew faster (617.0% against 33.9%). Krystal Biotech kept more of each dollar of sales as profit: a net margin of 52.6% against 52.3%.
| Latest fiscal year | CormedixCRMD, 2025 | Krystal BiotechKRYS, 2025 |
|---|---|---|
| Revenue | $312m | $389m |
| Revenue growth | 617.0% | 33.9% |
| Net income | $163m | $205m |
| Operating margin | — | 41.5% |
| Net margin | 52.3% | 52.6% |
| Return on equity | 66.6% | 18.9% |
| Free cash flow | $173m | $189m |
| Cash | $145m | $496m |
| Total debt | $144,626 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 191 | — |
| Market value | $428m | $9.00bn |
| Price vs our value range | Below our value range | Within our value range |
| Moat score | 7 (Weak) | — |
| Insider trades, 12 months | 0 buys, 8 sales | 0 buys, 142 sales |